Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

RBX 2660

Drug Profile

RBX 2660

Alternative Names: Faecal microbiota transplant - Rebiotix; fecal microbiota, live – jslm; Microbiota restoration therapy; Microbiota suspension; RBX-2660; REBYOTA

Latest Information Update: 09 Feb 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Rebiotix
  • Developer McMaster Childrens Hospital; Rebiotix; University of Alberta
  • Class Anti-inflammatories; Bacteria
  • Mechanism of Action Bacteria replacements; Gastrointestinal microbiome modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Clostridium infections
  • New Molecular Entity No

Highest Development Phases

  • Marketed Clostridium difficile infections
  • Phase I/II Hepatic encephalopathy; Urinary tract infections
  • No development reported Crohn's disease; Ulcerative colitis; Vancomycin-resistant enterococcal infections

Most Recent Events

  • 11 Oct 2023 Efficacy data from the phase III PUNCH CD3 trial in Clostridium difficile infections presented at the IDWeek 2023
  • 11 Oct 2023 Adverse events and efficacy data from the phase II PUNCH Open Label trial in Clostridium difficile infections released by Ferring Pharmaceuticals
  • 11 Oct 2023 The efficacy and adverse events data from the phase III PUNCH CD3-OLS trial in Clostridium difficile infection released by Ferring Pharmaceuticals
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top